Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cian HealthcareBOM:542678 49 FCF Yield % is 1,202.25 as of Aug. 12, 2026, which is 15274% above its 10-year median of 7.82. GuruFocus rates BOM:542678 with a GF Score™ of 49/100 and a GF Value™ of ₹82.33 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Cian Healthcare ranks better than 99.8% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cian Healthcare FCF Yield % Related Terms
Cian Healthcare FCF Yield % Historical Data
* Premium members only.
The historical data trend for Cian Healthcare's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542678 vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cian Healthcare's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cian Healthcare FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cian Healthcare's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Cian Healthcare's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cian Healthcare (BOM:542678) has a FCF Yield % of 1,202.25 as of Aug. 12, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cian Healthcare and its competitors. This is 15274% above median its historical median of 7.82. According to the industry distribution chart, Cian Healthcare ranks #2 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is Cian Healthcare's FCF Yield % too high?
Cian Healthcare's current FCF Yield % of 1,202.25 is 15274% above median its 10-year median of 7.82. The Drug Manufacturers industry median FCF Yield % is 0.64. Cian Healthcare's value of 1,202.25 is 187751.6% above this industry median. Based on the distribution chart, Cian Healthcare ranks #2 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cian Healthcare has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cian Healthcare's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cian Healthcare ranks #2 out of 1005 companies for FCF Yield %. This places Cian Healthcare in the top 0% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.64. Cian Healthcare's value of 1,202.25 is 187751.6% above this benchmark. While the company's 10-year median is 7.82 vs. the industry median of 0.64, Cian Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.64, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cian Healthcare's current FCF Yield % of 1,202.25 is 187751.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cian Healthcare and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cian Healthcare's current FCF Yield % is 1,202.25, which is 15274% above median its own 10-year median of 7.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cian Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Cian Healthcare (BOM:542678) is currently considered Possible Value Trap. The stock's GF Value™ is ₹82.33, compared to a current price of ₹9.55 — trading 88.4% below its estimated fair value. The current FCF Yield % is 1,202.25, which is 15274% above median its 10-year median of 7.82 and 187751.6% above the Drug Manufacturers industry median of 0.64. Cian Healthcare's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cian Healthcare (BOM:542678), the current FCF Yield % is 1,202.25 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cian Healthcare (BOM:542678) Overvalued in 2026?
Based on GuruFocus' analysis, Cian Healthcare stock appears to be undervalued.
The current stock price of ₹9.55 is trading 88.4% below its estimated GF Value™ of ₹82.33.
GuruFocus considers Cian Healthcare to be Possible Value Trap.
Key valuation signals for BOM:542678:
FCF Yield %: 1,202.25 (15274% above median its 10-year median of 7.82)
GF Value™: ₹82.33 vs. price of ₹9.55 (88.4% below fair value)
Industry Position: 187751.6% above the Drug Manufacturers median (#2 of 1005)
No single metric tells the full story. See the BOM:542678 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cian Healthcare Ltd is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company manufactures multiple product lines, including tablets, capsules, soft gels, liquid orals, ointments/creams and sachets, and cosmetics. Its portfolio comprises gynecology, haematinic, cardio-diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, vitamins, and nutrient products. The company operates in five sectors: Export, Government Supplies, Merchant Export, Own Brand Franchise Business, and Third Party/Contract Manufacturing.
49GF Score
Get the complete analysis for BOM:542678
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542678 has been successfully added to your 
